A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Recruiting · NCT05276726 · Interventional (participants receive a specific treatment) · Lead sponsor: Allist Pharmaceuticals, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.
- STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
- Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
- ECOG 0-1
Exclusion criteria
- Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
- Any severe and/or uncontrolled medical conditions
- Active infection requiring systemic treatment within 7 days
- Therapeutic radiation therapy within 3 weeks of study day 1
Where it is running
21 locations listed.
- Research site08 - Beijing, Beijing Municipality, China
- Research site09 - Beijing, Beijing Municipality, China
- Research site021 - Beijing, Beijing Municipality, China
- Research site02 - Beijing, Beijing Municipality, China
- Research site01 - Beijing, Beijing Municipality, China
- Research site013 - Beijing, Beijing Municipality, China
- Research site010 - Chongqing, Chongqing Municipality, China
- Research site05 - Xiamen, Fujian, China
- Research site011 - Shenzhen, Guangdong, China
- Research site016 - Nanning, Guangxi, China
- Research site017 - Shijiazhuang, Hebei, China
- Research site018 - Harbin, Heilongjiang, China
- Research site04 - Zhengzhou, Henan, China
- Research site012 - Changsha, Hunan, China
- Research site015 - Changchun, Jilin, China
- Research site06 - Shenyang, Liaoning, China
- Research site07 - Shenyang, Liaoning, China
- Research site014 - Hohhot, Neimenggu, China
- Research site020 - Xi’an, Shanxi, China
- Research site03 - Hubei, Wuhan, China
- Research site019 - Hangzhou, Zhejiang, China